Advertisement
"We are pleased with the ongoing government support and the opportunity tocontinue to advance our technology and applications in the biodefense arena,"said Michael Treble, President of Ibis and Vice President of Isis. "Thesecontracts support the Ibis business model to commercialize the Ibis T5000 inmultiple business sectors, including government biodefense and infectiousdisease surveillance, healthcare-associated infection control, infectiousdisease research and, in the future, in vitro diagnostics."
Advertisement
As part of the contracts awarded by DHS-S&T, Ibis will continue to developbroad biological applications to identify and characterize important bacterialand viral agents that are considered crucial to maintain homeland security.Ibis will also use the funding to advance the application of the Ibis T5000system in microbial forensics, a type of forensics used in the investigationof crimes involving infectious organisms. Under the DTRA contract, Ibis willbroaden its core technology in the area of biodefense through advances insample preparation to allow detection of trace amounts of broad groups ofmicrobial agents.
ABOUT THE IBIS T5000 BIOSENSOR SYSTEM AND IBIS BIOSCIENCES, INC.
Ibis Biosciences, Inc., a wholly owned subsidiary of Isis Pharmaceuticals,has developed the Ibis T5000 Biosensor System for rapid identification andcharacterization of infectious agents. The Ibis T5000 is capable ofidentifying virtually all bacteria, viruses and fungi, and can provideinformation about drug resistance, virulence and strain type of thesepathogens. Commercial applications for the Ibis T5000 Biosensor Systeminclude epidemiologic surveillance, monitoring of pandemic diseases,identification of emerging or previously unknown pathogens, forensiccharacterization of human samples, identification of sources ofhospital-associated infections, and, in the future, human infectious diseasediagnostics. Bruker Daltonics, a subsidiary of Bruker BioSciencesCorporation, is globally responsible for manufacture, order processing,installation and service of Ibis T5000 instruments. Ibis Biosciencesdevelops, manufactures and markets Ibis T5000 assay kits. Additionalinformation about Ibis Biosciences can be found by selecting the IbisBiosciences link from Isis' homepage at http://www.isispharm.com.
Ibis Biosciences has received development funding from U.S. governmentagencies including the Defense Advanced Research Projects Agency (DARPA), theNational Institute of Allergy and Infectious Diseases (NIAID), part of theNational Institutes of Health (NIH), the Centers for Disease Control andPrevention (CDC), the Federal Bureau of Investigation (FBI), the Department ofHomeland Security (DHS), and others.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop noveldrugs for its product pipeline and for its partners. The Company hassuccessfully commercialized the world's first antisense drug and has 17 drugsin deve
